We delivered 44% of a Phase 3 dermatology study's enrollment, at $2,260 per patient against a $117,819 industry average.

That same multi-channel engine, backed by a rare and complex-condition track record across 60+ advocacy partnerships in 25+ countries, is ready for your Hidradenitis Suppurativa trial.

Talk to our HS teamSee how it works →
20+
HS advocacy organizations and leaders
engaged globally, pre-enrollment
52x
Lower cost per enrollment
vs. industry average, completed Phase 3 AD program
60+
Rare and complex-condition partnerships
across Leapcure's portfolio
25+
Countries with advocacy-led recruitment
for rare and complex conditions

Understanding Hidradenitis Suppurativa as a Clinical Trial Indication

Hidradenitis suppurativa (HS) is a chronic, inflammatory skin disease marked by painful nodules, abscesses, and sinus tracts in the armpits, groin, and other skin folds. It affects roughly 1 in 100 people, yet it is widely underdiagnosed and often mistaken for recurrent boils or ordinary infections for years before a specialist confirms it. Disease severity is commonly staged from Hurley I to III, and most trials require moderate-to-severe patients with a minimum inflammatory lesion count, which narrows an already hidden population.

For sponsors, that combination makes HS one of dermatology's harder indications to enroll. Diagnostic delay means many eligible patients are still years from a specialist, the population is dispersed rather than concentrated at large centers, and the visible, intimate nature of the disease drives stigma that keeps patients from raising their hand. The patients a protocol needs are reached mainly through the advocacy communities and patient leaders they already trust, and those relationships are the hardest asset for a recruitment partner to build after a trial is already behind.

Leapcure brings three distinct assets to an HS trial, each honestly scoped. First, a real HS network: through a dedicated HS insights and advocacy-engagement initiative, Leapcure has engaged 20+ hidradenitis suppurativa advocacy organizations and patient leaders globally, activated relationship infrastructure most recruitment partners cannot find or access. Second, dermatology infrastructure proven in an adjacent indication: in a completed Phase 3 atopic dermatitis program, that same multi-channel engine enrolled 58 patients, 44% of the entire study, at a blended $2,260 per enrollment against a sponsor-reported industry benchmark of $117,819. Third, a rare and complex-condition track record spanning 60+ advocacy partnerships across 25+ countries, supported by a Patient Success Team built for sensitive populations. These are separate proof points. Leapcure does not have a completed HS enrollment result yet, and none of the dermatology or portfolio figures should be read as one.

The Challenge

Hidradenitis suppurativa recruitment demands more than reach. It demands advocacy access others cannot build fast, and sensitive support that gets eligible patients to the site.

The HS community is reached through advocacy access others cannot build fast

Hidradenitis suppurativa patients cluster in the advocacy communities, online groups, and patient-leader networks they trust, not at a handful of large referral centers. Those relationships take months to build authentically, and a recruitment partner that starts from zero after a trial opens is already behind.

Leapcure has engaged 20+ HS advocacy organizations and patient leaders globally through a dedicated HS advocacy-engagement initiative. This is real, activated HS-specific relationship infrastructure that exists before your trial opens, not a claim of prior HS enrollment.

Diagnostic delay hides eligible HS patients for years

HS is widely underdiagnosed and frequently mistaken for recurrent boils or ordinary skin infections, so many patients who would qualify for a moderate-to-severe protocol have not yet reached a specialist. The eligible population is also dispersed across regions rather than concentrated, which makes site-only recruitment slow.

Leapcure's advocacy-led, education-first model reaches patients where they already are and helps them understand HS and their trial options, drawing on a Patient Success Team experienced across rare and complex conditions.

Stigma keeps HS patients from raising their hand

Because HS affects intimate areas of the body and carries visible, painful symptoms, many patients are reluctant to discuss it or to consider a trial at all. Recruitment that ignores this loses eligible, motivated patients at the doorstep.

Leapcure's Patient Success Team supports patients and families with the sensitivity these communities require, from first engagement through to the site, the same high-touch model proven across our rare and complex-condition portfolio.

Sponsors need proof a partner can actually deliver dermatology enrollment

An engaged community is necessary but not sufficient. Sponsors also need evidence that a partner can convert reach into enrolled, pre-screened patients at a cost that beats broad advertising, and can hold a timeline across countries.

In a completed Phase 3 atopic dermatitis program, Leapcure's multi-channel engine delivered 58 enrollments, 44% of the study, at $2,260 per enrollment versus a $117,819 industry benchmark. This is adjacent dermatology proof, not an HS result.

Three Steps. One Advocacy-Led Strategy for Your HS Trial.

Leapcure starts from an HS network it already holds, layers on a dermatology engine proven in a completed Phase 3, and supports patients through to the site, mapped to your protocol, your sites, and your timeline.

1

Activate the existing HS advocacy network

Leapcure begins from relationships it already holds: 20+ engaged HS advocacy organizations and patient leaders worldwide. Content is co-developed with these partners so research reaches patients through voices they already trust, rather than as an unsolicited pitch, and outreach can start without the months-long ramp of building a community from scratch.

2

Apply the dermatology multi-channel engine proven in AD

On top of the HS network, Leapcure runs the same precision-digital and pre-screening engine that delivered 44% of a completed Phase 3 atopic dermatitis study. Every patient is pre-screened against the protocol's criteria, including severity staging and lesion counts, and educated on the study before site referral, so sites receive enrollment-ready candidates rather than referrals that create coordinator work.

3

Optimize weekly with Patient Success support through to the site

Channel mix and site support are rebalanced weekly against referral quality and site capacity, while Leapcure's Patient Success Team supports patients and families with the sensitivity HS requires, from first engagement through to the site visit. This keeps enrollment moving across regions and reduces the drop-off that stigma and logistics otherwise cause.

Adjacent Proof: A Completed Phase 3 Atopic Dermatitis Program. Dermatology Infrastructure, Not an HS Result.

Challenge Context

Indication

Moderate-to-severe atopic dermatitis, Phase 3 (adjacent dermatology indication, not HS)

Sites

22 active sites with Leapcure enrollments across the US, Poland, and Germany

Why it is shown

Evidence that Leapcure's multi-channel dermatology engine converts reach into enrolled, pre-screened patients at a fraction of industry cost. A completed HS enrollment result does not exist yet.

Channels deployed

Precision digital as the primary engine, supported by eczema and dermatitis advocacy communities and a patient-support model coordinated across 3 countries.

Results & Metrics

Patients enrolled

58 patients enrolled by Leapcure, 44% of all participants in the study.

Cost efficiency

$2,260 blended enrollment acquisition cost versus a sponsor-reported industry benchmark of $117,819, roughly 52x lower, with an estimated $3.9M in global savings. Acquisition cost varies by protocol, phase, site selection, and channel mix.

Funnel

221 patients pre-screened, educated, and scheduled for ICF before site assignment.

Enrollment speed

Enrollment completed in roughly 12 months, faster than the approximately 18-month average recruitment period for industry-sponsored Phase 3 trials.

Indication note

This is a completed atopic dermatitis program, included as adjacent dermatology infrastructure proof. It is not a hidradenitis suppurativa enrollment result.

Five Capabilities. Built for Hidradenitis Suppurativa. Active Before Your Trial Opens.

Leapcure brings an AD-proven dermatology engine, an HS-specific advocacy network, a sensitive patient-support model, cross-portfolio rare and complex-condition experience, and AEO/AI-search visibility delivered to your trial.

Dermatology Multi-Channel Digital Engine (AD-proven)

  • •Precision digital as the primary driver: search, social, and condition-specific community placements, the same engine that delivered 44% of a completed Phase 3 atopic dermatitis study.
  • •Every patient is pre-screened against the protocol's severity staging and lesion-count criteria and educated before site referral.
  • •Blended enrollment acquisition cost of $2,260 in that AD program versus a $117,819 industry benchmark. This is adjacent dermatology proof, not an HS result.

HS Advocacy Network (HS-specific)

  • •20+ hidradenitis suppurativa advocacy organizations and patient leaders engaged globally through a dedicated HS insights and advocacy-engagement initiative.
  • •Content is co-developed with HS partners so research reaches patients through trusted voices, not unsolicited outreach.
  • •This is real, activated HS-specific relationship infrastructure, built before a trial opens, not a claim of prior HS enrollment.

Patient Support Model

  • •A Patient Success Team supports patients and families with the sensitivity HS requires, from first engagement through to the site.
  • •Support addresses stigma, logistics, and study expectations, the barriers that otherwise cause eligible HS patients to drop out of the funnel.
  • •The same high-touch model is proven across Leapcure's rare and complex-condition portfolio.

Rare and Complex-Condition Experience

  • •60+ advocacy partnerships across 25+ countries in rare and complex conditions.
  • •Experience recruiting sensitive, hard-to-reach populations where trust and education decide whether patients enroll.
  • •This is cross-portfolio experience, a broader claim than the HS-specific network above, and the two are never combined into a single number.

AEO and AI-Search Visibility for Your Trial

  • •HS patients increasingly ask ChatGPT, Perplexity, and Google's AI Overview which trials they may be eligible for. Leapcure makes your trial's information genuinely retrievable by these engines.
  • •That means crawlable, server-rendered content with clear answer passages, unique first-party data, cited sources, and presence in the communities AI engines actually cite. It is good content structure plus real authority, not schema tricks or AI markup.
  • •As AI search grows as a patient-discovery path, this channel compounds over the life of your study.

Living with Hidradenitis Suppurativa? A trial may be an option.

If you are living with hidradenitis suppurativa, a clinical trial may give you access to investigational treatments that are not yet widely available. We know HS can be painful, exhausting, and hard to talk about, and that researching trial options on top of daily flares is a lot to carry. Leapcure's team offers step-by-step, private support, and we include your family or caregivers wherever that helps.

See if an HS trial may be right for you
Leapcure kangaroo mascot

Leapcure brings three honestly-scoped assets to a hidradenitis suppurativa trial: a global HS advocacy network of 20+ engaged organizations and patient leaders, dermatology recruitment infrastructure proven in a completed Phase 3 atopic dermatitis program (58 patients, 44% of the study, at a fraction of the industry benchmark for acquisition cost), and a rare and complex-condition track record across 60+ advocacy partnerships in 25+ countries. Leapcure does not have a completed HS enrollment result yet, and we can mobilize within 48 hours of program launch.

Talk to our HS team